Pinnacle Associates LTD Cytokinetics Inc Transaction History

Pinnacle Associates LTD

  • $6.17 Billion
  • Q1 2024

A detailed history of Pinnacle Associates LTD transactions in Cytokinetics Inc stock. As of the latest transaction made, Pinnacle Associates LTD holds 257,167 shares of CYTK stock, worth $13.9 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares
257,167
Previous 258,358 0.46%
Holding current value
$13.9 Million
Previous $21.6 Million 16.42%
% of portfolio
0.29%
Previous 0.37%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 26, 2024
SELL
$63.75 - $108.06 $75,926 - $128,699
-1,191 Reduced 0.46%
257,167 $18 Million
Q4 2023

Jan 19, 2024
SELL
$26.88 - $83.49 $26,100 - $81,068
-971 Reduced 0.37%
258,358 $21.6 Million
Q3 2023

Oct 23, 2023
SELL
$29.46 - $36.61 $325,002 - $403,881
-11,032 Reduced 4.08%
259,329 $7.64 Million
Q2 2023

Jul 26, 2023
SELL
$32.62 - $40.75 $314,619 - $393,033
-9,645 Reduced 3.44%
270,361 $8.82 Million
Q1 2023

May 04, 2023
SELL
$33.36 - $45.71 $158,093 - $216,619
-4,739 Reduced 1.66%
280,006 $9.85 Million
Q4 2022

Jan 31, 2023
BUY
$35.77 - $51.11 $24,466 - $34,959
684 Added 0.24%
284,745 $13 Million
Q4 2022

Jan 25, 2023
SELL
$35.77 - $51.11 $207,108 - $295,926
-5,790 Reduced 2.0%
284,061 $0
Q3 2022

Oct 31, 2022
SELL
$38.54 - $54.52 $396,769 - $561,283
-10,295 Reduced 3.43%
289,851 $14 Million
Q2 2022

Aug 02, 2022
SELL
$33.93 - $48.92 $44,719 - $64,476
-1,318 Reduced 0.44%
300,146 $11.8 Million
Q1 2022

May 05, 2022
SELL
$29.74 - $46.0 $408,270 - $631,488
-13,728 Reduced 4.36%
301,464 $11.1 Million
Q4 2021

Feb 02, 2022
SELL
$34.35 - $46.38 $69,490 - $93,826
-2,023 Reduced 0.64%
315,192 $14.4 Million
Q3 2021

Oct 19, 2021
SELL
$18.54 - $35.74 $225,817 - $435,313
-12,180 Reduced 3.7%
317,215 $11.3 Million
Q2 2021

Aug 02, 2021
BUY
$19.79 - $26.99 $100,849 - $137,541
5,096 Added 1.57%
329,395 $6.52 Million
Q1 2021

May 12, 2021
SELL
$18.57 - $25.68 $657,842 - $909,714
-35,425 Reduced 9.85%
324,299 $7.54 Million
Q4 2020

Jan 26, 2021
SELL
$15.26 - $28.61 $371,382 - $696,281
-24,337 Reduced 6.34%
359,724 $7.48 Million
Q3 2020

Oct 23, 2020
SELL
$20.58 - $28.96 $311,107 - $437,788
-15,117 Reduced 3.79%
384,061 $8.32 Million
Q2 2020

Aug 14, 2020
SELL
$11.15 - $24.64 $41,422 - $91,537
-3,715 Reduced 0.92%
399,178 $9.41 Million
Q1 2020

May 13, 2020
SELL
$8.75 - $16.3 $626,351 - $1.17 Million
-71,583 Reduced 15.09%
402,893 $4.75 Million
Q4 2019

Feb 03, 2020
SELL
$7.95 - $11.84 $358,505 - $533,924
-45,095 Reduced 8.68%
474,476 $5.03 Million
Q3 2019

Nov 08, 2019
SELL
$10.82 - $14.25 $292,951 - $385,818
-27,075 Reduced 4.95%
519,571 $5.91 Million
Q2 2019

Aug 05, 2019
SELL
$7.95 - $11.25 $427,248 - $604,597
-53,742 Reduced 8.95%
546,646 $6.15 Million
Q1 2019

May 10, 2019
BUY
$5.95 - $10.19 $45,279 - $77,545
7,610 Added 1.28%
600,388 $4.86 Million
Q4 2018

Feb 05, 2019
SELL
$5.91 - $9.29 $333,991 - $525,005
-56,513 Reduced 8.7%
592,778 $3.75 Million
Q3 2018

Nov 13, 2018
SELL
$6.4 - $9.85 $697,817 - $1.07 Million
-109,034 Reduced 14.38%
649,291 $6.4 Million
Q2 2018

Aug 08, 2018
SELL
$6.9 - $9.9 $897,621 - $1.29 Million
-130,090 Reduced 14.64%
758,325 $6.29 Million
Q1 2018

May 11, 2018
BUY
$7.2 - $10.05 $78,048 - $108,942
10,840 Added 1.24%
888,415 $6.4 Million
Q4 2017

Feb 12, 2018
SELL
$7.25 - $15.65 $951,417 - $2.05 Million
-131,230 Reduced 13.01%
877,575 $7.15 Million
Q3 2017

Nov 13, 2017
BUY
$12.0 - $15.0 $12.1 Million - $15.1 Million
1,008,805
1,008,805 $14.6 Million

Others Institutions Holding CYTK

# of Institutions
459
Shares Held
108M
Call Options Held
7.2M
Put Options Held
6.2M
View Full List

About CYTOKINETICS INC

CYTK Quotes by TradingView
  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $5.1B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Pinnacle Associates LTD Portfolio

Follow Pinnacle Associates LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pinnacle Associates LTD, based on Form 13F filings with the SEC.

News

Stay updated on Pinnacle Associates LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email